Major success for our Scottish Life Sciences sector at this year’s Queen’s Awards for Enterprise with wins from Optos, Tissue Solutions and PHASTAR. Optos business’ mission to save eyesight is recognised by Queen’s Awards Optos, a Fife-based company, that specialises in the design and manufacture of advanced retinal imaging technology has been recognised for its innovation with a 2019 Queen’s Award for Enterprise. Optos, which...
Omega Diagnostics, the Alva-based medical testing kit developer, said it had made “significant progress” restructuring its business as it flagged full-year results in line with market hopes. In a trading update, the group noted that revenues for the year to the end of March 2019 would be around £9.74 million. While that would mark a 28 per cent decline on the year before, Omega has...
Lamellar Biomedical Limited (Lamellar), an innovative biotechnology company pioneering new approaches for the safe and effective transfer of functional nucleic acids with its LAMELLASOME™ NAT platform, announces the creation of additional capacity through its expansion into the BioCity biotech incubator, Glasgow. The dedicated formulation and process facility will enable Lamellar to meet the need for increased capacity as its technology attracts growing interest from external...
A study has identified chemicals in the skin responsible for a unique scent in people with Parkinson’s disease. The chemicals can be detected in an oily substance secreted from the skin called sebum, the researchers found. The findings suggest Parkinson’s disease could one day be diagnosed from skin swabs, potentially leading to new tests. Super smeller There are no tests for Parkinson’s disease at present....
Clackmannanshire biotechnology business Omega Diagnostics expects its turnover to rise to over £50 million in the next five years after beginning the commercialisation of one of its key HIV-related products. The business, which is headquartered in Alva, makes diagnostic tests that focus on HIV, allergies and food intolerances, but only the latter part of the business currently generates revenues. Chief executive Colin King said he expects the...
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has received its first purchase orders for its VISITECT® CD4 350 cut-off test and continues to make progress with its VISITECT® CD4 Advanced Disease test. VISITECT® CD4 350 cut-off test The Company is pleased to report that it has received its first purchase orders for its CE-Marked...